

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/541,394
				Filing Date	July 1, 2005
				First Named Inventor	Matti KIVIKKO
				Art Unit	UNASSIGNED
				Examiner Name	UNASSIGNED
Sheet	1	of	1	Attorney Docket Number	06267.0128

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CS		RE 38,102	29 Apr. 2003	Haikala et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code ³ Number ⁴ Kind Code ⁶ (if known)				
CS		WO 99/66932	29 Dec. 1999			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
CS		J. Lilleberg et al., "Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with Left Ventricular Dysfunction," J. Cardiovasc Pharmacol, Vol. 26 (Suppl. 1), pages S63-S69 (1995)	
CS		Stig Sundberg et al., "Hemodynamic and Neurohumoral Effects of Levosimendan, a New Calcium Sensitizer, at Rest and During Exercise in Healthy Men," The American Journal of Cardiology, Vol. 75, pages 1061-1066 (1995)	
CS		Esa-Pekka Sandell et al., "Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart Failure," J Cardiovasc Pharmacol, Vol. 26 (Suppl. 1), pages S57-S62 (1995)	

Examiner Signature		Date Considered	9/11/2007
-----------------------	---	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	UNASSIGNED 10/541394
		Filing Date	Filed Herewith
		First Named Inventor	Matti KIVIKKO
		Art Unit	UNASSIGNED
		Examiner Name	UNASSIGNED
		Attorney Docket Number	06267.0128
Sheet	1	of	1

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
CR		WO 92/12135	23 July 1992			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
CR		XP00228338 & JP 04 368328 A (Teikoku Hormone Mfg Co Ltd) 21 December 1992 (1992-12-21) abstract, "Agent for treating chronic renal failure - contains 6-(4-acetyl-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone."	
CR		Paul S. Pagel et al., "Pharmacology of Levosimendan: A New Myofilament Calcium Sensitizer," Cardiovascular Drug Reviews, Vol. 14, No. 3, pp. 286-316, 1996	
CR		Paul S. Pagel et al., "Influence of levosimendan, plmobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs," British Journal of Pharmacology, Vol. 119, pp. 609-615, 1996	

Examiner Signature	<i>Chris Stone</i>	Date Considered	9/11/2007
-----------------------	--------------------	--------------------	-----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.